Pre-made Biciromab benchmark antibody (Radiolabelled antibody, anti-fibrin II therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab’ fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]